BioCentury | Dec 2, 2020
Finance

Canbridge broadens investor syndicate with $43M series E

...in that territory, and sells oral mucositis drug Caphosol in China under a deal with EUSA Pharma...
BioCentury | Apr 2, 2020
Product Development

COVID-19 roundup: EMA seeks to rein in chloroquine use; plus cash for CEPI, WHO’s SOLIDARITY grows, CytoDyn, EUSA, Chembio, PCR Biosystems and more

...already received leronlimab under an emergency IND. CytoDyn shares gained $0.40 (15%) to $3.07 Wednesday. EUSA Pharma Ltd....
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

...Giovanni XXIII Hospital has initiated an observational case-control clinical trial, SISCO, of Sylvant siltuximab from EUSA Pharma Ltd....
...Interferon γ Sandi Wong, Assistant Editor Kineret, anakinra (Interleukin-1ra (IL-1ra)) Gamifant, emapalumab-lzsg (NI-0501) Swedish Orphan Biovitrum AB Roivant Sciences GmbH EUSA Pharma Ltd. CanSino...
BioCentury | Feb 19, 2020
Finance

Eyeing IPO, Canbridge raises $98M to advance, commercialize products

...for mucopolysaccharidosis II (MPS II, Hunter syndrome). The company holds Chinese rights to Caphosol from EUSA Pharma Ltd....
BioCentury | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

...in October. BeiGene takes local rights to two EUSA products Via a deal with U.K.-based EUSA Pharma Ltd....
...#), MDX-010 (Compound #), BMS-734016 (Compound #), ipilimumab (Generic), Yervoy (Other) Insilico Medicine Inc. Pfizer Inc. NHS England Novartis AG EUSA Pharma Ltd. BeiGene...
BioCentury | Dec 13, 2019
Preclinical News

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

...flares, were lower at day 8 in patients who responded to the anti-IL-6 mAb from EUSA Pharma Ltd....
BioCentury | Jul 10, 2019
Clinical News

Michael Becker, patient advocate and biotech exec, dies at 50

...and director for several publicly traded biotechnology companies, including cancer companies Cytogen Corp. (acquired by EUSA Pharma...
BioCentury | May 15, 2019
Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

...CMO. She was CMO at DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT). Cancer and rare disease company EUSA Pharma Ltd....
...Cohen was VP, clinical development leader at Pfizer Inc. (NYSE:PFE). Hongjiang Li, Staff Writer Avita Medical Ltd. Biogen Inc. Bionure EUSA Pharma Ltd. Rubius...
BioCentury | Mar 14, 2019
Preclinical News

Antibody-drug conjugate against ALK could selectively treat neuroblastoma

...marketed drug dinutuximab. Unituxin dinutuximab from United Therapeutics Corp. (NASDAQ:UTHR) and Qarziba dinutuximab beta from EUSA Pharma Ltd....
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
Items per page:
1 - 10 of 124
BioCentury | Dec 2, 2020
Finance

Canbridge broadens investor syndicate with $43M series E

...in that territory, and sells oral mucositis drug Caphosol in China under a deal with EUSA Pharma...
BioCentury | Apr 2, 2020
Product Development

COVID-19 roundup: EMA seeks to rein in chloroquine use; plus cash for CEPI, WHO’s SOLIDARITY grows, CytoDyn, EUSA, Chembio, PCR Biosystems and more

...already received leronlimab under an emergency IND. CytoDyn shares gained $0.40 (15%) to $3.07 Wednesday. EUSA Pharma Ltd....
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

...Giovanni XXIII Hospital has initiated an observational case-control clinical trial, SISCO, of Sylvant siltuximab from EUSA Pharma Ltd....
...Interferon γ Sandi Wong, Assistant Editor Kineret, anakinra (Interleukin-1ra (IL-1ra)) Gamifant, emapalumab-lzsg (NI-0501) Swedish Orphan Biovitrum AB Roivant Sciences GmbH EUSA Pharma Ltd. CanSino...
BioCentury | Feb 19, 2020
Finance

Eyeing IPO, Canbridge raises $98M to advance, commercialize products

...for mucopolysaccharidosis II (MPS II, Hunter syndrome). The company holds Chinese rights to Caphosol from EUSA Pharma Ltd....
BioCentury | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

...in October. BeiGene takes local rights to two EUSA products Via a deal with U.K.-based EUSA Pharma Ltd....
...#), MDX-010 (Compound #), BMS-734016 (Compound #), ipilimumab (Generic), Yervoy (Other) Insilico Medicine Inc. Pfizer Inc. NHS England Novartis AG EUSA Pharma Ltd. BeiGene...
BioCentury | Dec 13, 2019
Preclinical News

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

...flares, were lower at day 8 in patients who responded to the anti-IL-6 mAb from EUSA Pharma Ltd....
BioCentury | Jul 10, 2019
Clinical News

Michael Becker, patient advocate and biotech exec, dies at 50

...and director for several publicly traded biotechnology companies, including cancer companies Cytogen Corp. (acquired by EUSA Pharma...
BioCentury | May 15, 2019
Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

...CMO. She was CMO at DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT). Cancer and rare disease company EUSA Pharma Ltd....
...Cohen was VP, clinical development leader at Pfizer Inc. (NYSE:PFE). Hongjiang Li, Staff Writer Avita Medical Ltd. Biogen Inc. Bionure EUSA Pharma Ltd. Rubius...
BioCentury | Mar 14, 2019
Preclinical News

Antibody-drug conjugate against ALK could selectively treat neuroblastoma

...marketed drug dinutuximab. Unituxin dinutuximab from United Therapeutics Corp. (NASDAQ:UTHR) and Qarziba dinutuximab beta from EUSA Pharma Ltd....
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
Items per page:
1 - 10 of 124